Fig 1: DEPDC7 inhibits migration and invasion of hepatoma cells. (A) SK-Hep-1-DEPDC7, Huh7-DEPDC7 and NC cells that migrated through the membrane or invaded through the Matrigel-coated membrane were stained by crystal violet (magnification, ×200). (B and C) Quantification analysis of migration and invasion of (B) SK-Hep-1-DEPDC7 and (C) Huh7-DEPDC7 cells and their respective NC cells. The migrated cells were counted in ten random fields under a light microscope at ×200 magnification. Data are expressed as the mean ± standard deviation from three experiments. *P<0.05. DEPDC7, DEP domain-containing 7; NC, negative control.
Fig 2: DEPDC7 overexpression inhibits cell proliferation and colony formation. (A) Western blot analysis of DEPDC7-transfected SK-Hep-1 and Huh7 cells and NC cells. (B) Cell growth curve of SK-Hep-1-DEPDC7, Huh7-DEPDC7 and NC cells. Data are expressed as the mean ± standard deviation from 3 experiments *P<0.05. (C) Colony formation assay of SK-Hep-1-DEPDC7 or Huh7-DEPDC7 cells and NC cells (left panel). The right panel shows colony number of three experiments. Data are expressed as the mean ± standard deviation. *P<0.05 when compared with the negative control. (D) Immunochemical staining for Ki-67 in the SK-Hep-1 or Huh7 cells with or without infection of plv-DEPDC7. The granular brown-yellow-colored immunoreactivity is evidently increased in the NC groups compared with the DEPDC7 overexpression groups. (E) A semi-quantitative analysis of Ki-67 immunochemistry. Data are expressed as the mean ± standard deviation from 3 experiments. *P<0.05. DEPDC7, DEP domain-containing 7; NC, negative control.
Fig 3: DEPDC7 overexpression leads to cell cycle arrest in hepatoma cells. (A) Cell cycle profiles of SK-Hep-1-DEPDC7, Huh-7-DEPDC7 and NC cells. (B) Distribution of SK-Hep-1 cell numbers in different cycles. Data are expressed as the mean ± standard deviation from 3 experiments. *P<0.05. (C) Distribution of Huh-7 cell numbers in different cycles. Data are expressed as the mean ± standard deviation from 3 experiments. *P<0.05. DEPDC7, DEP domain-containing 7; NC, negative control.
Fig 4: DEPDC7 expression in hepatoma cell lines and tissues. (A) mRNA expression of DEPDC7 in the normal hepatic L-02 cell line and four hepatoma SMMC-7721, HepG2, SK-Hep-1 and Huh-7 cell lines. The expression levels were normalized to ß-actin. Data are expressed as the mean ± standard from 3 experiments. *P<0.05 was determined by ANOVA with Dunnett's post hoc test for comparison to L-02 cells. (B) The gray value of DEPDC7, which was normalized to that of ß-actin in L-02 cells and the four hepatoma cell lines. Data are expressed as the mean ± standard deviation from 3 experiments. *P<0.05 was determined by ANOVA with Dunnett's post hoc test for comparison to L-02 cells. (C) Western blot detection of DEPDC7 L-02 and four hepatoma cell lines. ß-actin acts as a loading control. (D) Immunohistochemistry of DEPDC7 of hepatoma tissues. The brown-yellowish staining is stronger on the adjacent normal tissue, in the right upper part of the section (adjacent normal tissue) compared with the left lower part of the section (hepatoma tissue). Scale bar, 50 µm. (E) Semi-quantitative observation DEPDC7 immunoreactivity of liver sections from 48 hepatoma cases. DEPDC7, DEP domain-containing 7; ANOVA, analysis of variance.
Supplier Page from Abcam for Anti-DEPDC7 antibody